Institutional Care Volume May Affect Clinical Outcomes in Multiple Myeloma

Share this content:
High-volume treatment centers tend to produce better clinical outcomes, but volume isn’t a necessary predictor of survival rates.
High-volume treatment centers tend to produce better clinical outcomes, but volume isn’t a necessary predictor of survival rates.

Medical center treatment volume may have an impact on clinical outcomes in multiple myeloma (MM), according to researchers at the Mayo Clinic. In a recent study, these researchers evaluated annual MM treatment volume and all-cause mortality using the National Cancer Database. All patients were diagnosed with MM between 2003 and 2011; it was found that patients may benefit from treatment at high-volume facilities.1

“One possibility is the ‘practice makes perfect' adage. This is especially true for multiple myeloma for several reasons,” said study author Ronald Go, MD, associate professor of medicine at the Mayo Clinic in Rochester, Minnesota.

It is estimated that there are only 2 new MM cases per hematologist/oncologist annually. There have been an unprecedented number of new drugs approved for MM in recent years (9 in the past 10 years), and an exponential increase in MM publications and clinical trials.

The researchers classified facilities by quartiles, balancing for patient clustering within facilities. They adjusted for demographic, socioeconomic (income, education, insurance type), and geographic (area of residence, treatment facility location, travel distance) factors. They also adjusted for comorbidity and year of diagnosis. In total, the analysis included 94,722 patients who were treated at 1 of 1333 facilities; the median age at diagnosis was 67 years and 54.7% were male.

The median annual facility volume was 6.1 patients per year; the unadjusted median overall survival by facility volume was 26.9 months for the lowest quartile, 29.1 months for the second quartile, 31.9 months for the third quartile, and 49.1 months for the fourth quartile. Facility volume was independently associated with all-cause mortality.

According to Dr Go, high-volume may be a reflection of good practices, such as “uniform use care pathways, adherence to clinical practice guidelines, discussion of complex cases at a tumor board, upfront chemotherapy dose-adjustment for frail patients, and preemptive management of treatment side effects. Determining these characteristics may help improve the outcome in lower-volume treatment facilities,” Dr Go told Cancer Therapy Advisor.

The study has significant limitations, however, due to its inability to control for selection bias by referring physicians. The researchers were also unable to account for the annual volume per physician or cumulative physician experience. Dr Go noted that there were lower-volume facilities that had as good outcomes as higher-volume facilities, and that some higher-volume facilities had outcomes similar to lower-volume facilities with poor survival rates. Volume is not, in itself, a necessary predictor of clinical outcomes.

Other studies suggest, however, that volume is an important factor. One study evaluating bone marrow transplant (BMT) centers and outcomes found that high patient to physician ratios tended to yield better outcomes.2

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs